Keywords: repligen, narrows, loss, fiscal, 4th-qtr, drugmaker, says
Repligen narrows loss 87% in fiscal 4th-qtr
Article | 18 June 2007
US drugmaker Repligen says that its total revenue for the fourth quarter of fiscal year 2007, ended March 31, 2007, was $3.7 million versus $2.8 ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Elan makes "transformational" acquisitions and a divestment
